08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Restrictive Covenants - A recent decision in the United States District Court, Middle District of F...
Read More >
While world governments scramble to contain the spread of the coronavirus, businesses are fielding q...
Read More >
On April 29, 2020, six Bay Area counties – Alameda, Contra Costa, Marin, San Francisco, San Mateo, ...
Read More >
Employer-sponsored health plans and health insurers may be required to post online - and to provide ...
Read More >
According to Part 541 of regulations issued by the U.S. Department of Labor under the Fair Labor Sta...
Read More >
In Peters v. WCAB (Cintas Corp), No. 1835 C.D. 2017, the Commonwealth Court was tasked with deciding...
Read More >